Hydrophilic Ferroferric Oxide Nanoparticles for T1 MRI Contrast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current MRI contrast agents, particularly gadolinium-based T1 contrast agents, pose risks due to brain deposition and nephrotoxicity, while ferroferric oxide nanoparticles primarily function as T2 contrast agents, generating dark signals, which limits their diagnostic effectiveness as T1 contrast agents.
Innovation Solution
Development of magnetic ferroferric oxide nanoparticles with a hydrophilic macromolecule, specifically designed to have a particle size between 2-5 nm, optimal electrokinetic potential, and high stability, enhancing their r1 value and reducing the r2/r1 ratio, thereby improving their suitability as a safe and reliable T1 contrast agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ferroferric oxide particle size is increased to improve saturation magnetization and r2 value, then magnetic properties are enhanced, but the nanoparticle can no longer function as an effective T1 contrast agent
Solution Approach 1:
The patent precisely controls the particle size parameter of ferroferric oxide nanoparticles to be less than 5 nm, which is a critical threshold. This parameter change enables the nanoparticles to exhibit T1 contrast agent characteristics (positive contrast, bright signal) rather than T2 characteristics (negative contrast, dark signal), while maintaining sufficient magnetic properties for effective imaging
2Measurement precision
If gadolinium-based contrast agents are used to achieve high r1 values and good imaging效果, then imaging quality is improved, but safety risks increase due to brain deposition and nephrotoxicity
Solution Approach 1:
The patent replaces the expensive and toxic gadolinium-based contrast agents with ferroferric oxide nanoparticles, which are biocompatible and safer for clinical use. The iron-based nanoparticles provide an alternative that achieves comparable or superior imaging performance without the harmful side effects of gadolinium accumulation in the brain and kidneys
Solution Approach 2:
The patent creates a composite structure by coating ferroferric oxide nanoparticles with hydrophilic polymers (such as PEG, PVA, or dextran). This composite approach improves water solubility, enhances circulation time in the bloodstream, and provides additional safety and stability, making the nanoparticles suitable for clinical T1 contrast agent applications
3Reliability
If ferroferric oxide is used as T2 contrast agent to achieve high r2 value, then magnetic contrast is improved, but clinical application is limited due to dark signal generation
Solution Approach 1:
The patent changes the particle size parameter of ferroferric oxide to less than 5 nm, which fundamentally alters the contrast mechanism from T2 (dark signal) to T1 (bright signal). This parameter change makes the contrast agent more compatible with clinical diagnostic practices, where bright signals are generally preferred for lesion detection and characterization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles demonstrate improved water solubility, stability, and imaging efficacy, offering a safer alternative to gadolinium-based agents with enhanced r1 values and reduced r2/r1 ratios, suitable for clinical use as T1-weighted MRI contrast agents.
Implementation Method 1
the hydrophilic macromolecule is adsorbed on a surface of the ferroferric oxide
Implementation Method 2
The MRI contrast agent may react with hydrogen proton, thus shortening longitudinal relaxation time (T1) or transverse relaxation time (T2) of the proton
Data Source
AI summary
The present invention discloses a magnetic ferroferric oxide nanoparticle, and a preparation method therefor and the use thereof. The magnetic ferroferric oxide nanoparticle contains ferroferric oxide and a hydrophilic macromolecule, wherein the ferroferric oxide and the hydrophilic macromolecule are in at least one of the following relationships (1) and (2): (1) the hydrophilic macromolecule is adsorbed on the surface of the ferroferric oxide; and (2) the ferroferric oxide and the hydrophilic macromolecule are in the state of mutual embedding or occlusion. In the present invention, the hydrophilic macromolecule is used as a stabilizer, and ferrous ions and ferric ions form the magnetic ferroferric oxide nanoparticle by means of coprecipitation; and the magnetic ferroferric oxide nanoparticle has a relatively high longitudinal magnetic relaxation rate r1, a relatively low transverse/longitudinal magnetic relaxation rate ratio (r2/r1), good water solubility, high stability, and good biocompatibility, and can be used as a contrast agent for T1-weighted magnetic resonance imaging (MRI) to improve the contrast and sensitivity of MRI.